Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Findeep phase II neoadjuvant tislelizumab plus chemotherapy in resectable stage II-IIIB (N2) NSCLC
ChiCTR2300069552Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Major pathologic response. Started Mar 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300069552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069552.